Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

CTCP
60142
CITAL
83730
peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant
diseases. Clin Cancer Res 2004 Oct;10:6897-6904 2. Cohen SJ, Punt CJ, Iannotti N, et al: Relationship
of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients
with metastatic colorectal cancer. J Clin Oncol 2008 Jul;26(19):3213-3221 3. Cohen SJ, Punt CJ,
Iannotti N, et al: Prognostic significance of circulating tumor cells in patients with metastatic colorectal
cancer. Ann Oncol 2009;20(7):1223-1229 4. Package insert: CellSearch Circulating Tumor Cell (CTC)
Kit. Veridex, LLC, Raritan, NJ
Circulating Tumor Cells (CTC) for Prostate Cancer by
CellSearch, Blood
Clinical Information: According to the American Cancer Society, prostate cancer claims
approximately 28,000 lives each year, the vast majority of which are a result of metastatic disease.
Although there are many options for the treatment of metastatic prostate cancer, oncologists often have to
wait several months after initiation of treatment before they can determine if the treatment is beneficial to
the patient. The CellSearch System identifies and enumerates the number of circulating tumor cells
(CTCs) in a blood specimen.(1) Studies suggest that the number of CTCs is associated with
progression-free and overall survival in patients with metastatic prostate cancer.(2,3)
Useful For: An aid in the monitoring of patients with metastatic prostate cancer
Interpretation: In patients with metastatic prostate cancer, the finding of > or =5 circulating tumor
cells/7.5 mL of blood is predictive of shorter progression-free survival and overall survival.(2)
Reference Values:
An interpretive report will be provided.
Clinical References: 1. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the
peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant
diseases. Clin Cancer Res 2004 Oct;10:6897-6904 2. deBono JS, Scher HI, Montgomery RB, et al:
Circulating tumor cells predict survival benefit from treatment in the metastatic castration-resistant
prostate cancer. Clin Cancer Res 2008 October 1;14(19):6302-6309 3. Danila DC, Heller G, Gignac GA,
et al: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin
Cancer Res 2007 December 1;13(23):7053-7058
Citalopram, Serum
Clinical Information: Citalopram (Celexa) and S-citalopram (escitalopram, Lexapro) are approved
for treatment of depression. Celexa is a racemic mixture containing equal amounts of R- and
S-enantiomer. Metabolites of citalopram (N-desmethylcitalopram) are less active than citalopram and do
not accumulate in serum to clinically significant concentration. Citalopram metabolism is carried out by
cytochrome P450 (CYP) 2C19 and 3A4-5. CYP 2D6 may play a minor role in citalopram metabolism.
Citalopram is known to reduce CYP 2D6 activity. Citalopram clearance is significantly affected by
reduced hepatic function, but only slightly by reduced renal function. A typical Celexa dose administered
to an adult is 40 mg per day. A typical Lexapro dose is 20 mg per day. Citalopram is 80% protein bound,
and the apparent volume of distribution is 12 L/Kg. Bioavailability is 80% and protein binding is 56% for
either form of the drug. Time to peak serum concentration is 4 hours, and the elimination half-life is 35
hours. Half-life is increased in the elderly. Dosage reductions may be necessary for patients who are
elderly or have reduced hepatic function.
Useful For: Monitoring citalopram therapy While regular blood level monitoring is not indicated in
most patients, the test is useful to identify noncompliance When used in conjunction with CYP 2C19 and
CYP 3A4-5 genotyping, the test can identify states of altered drug metabolism
Interpretation: Steady-state serum concentrations associated with optimal response to citalopram are
in the range of 100 to 250 ng/mL when the patient is administered the R,S-enantiomeric mixture (Celexa)
and 50 to 130 ng/mL when S-citalopram (Lexapro) is administered. The most common toxicities
Current as of January 3, 2013 2:22 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 478